Autogenous bone grafts from the iliac crest have long been the gold standard for repair and reconstruction of bone; however harvesting of the grafts from the iliac crest is associated with donor site morbidity, particularly chronic pain. The bone morphogenetic proteins (BMPs) are soluble bone matrix glycoproteins that induce the differentiation of osteoprogenitor cells into osteogenic cells and have the potential to act as autogenous bone graft substitutes. BMP-2, which can be produced with recombinant technology, is highly osteoinductive, inducing bone formation by stimulating the differentiation of mesenchymal cells into chondroblasts and osteoblasts. At present, more than 1,000 patients have received rhBMP-2 in clinical trials for acute open tibial fracture and interbody fusion procedures for the treatment of degenerative disc disease. Data suggest that rhBMP-2 therapy may offer an effective alternative to autogenous bone graft for recalcitrant bone unions and spinal fusion, obviating donor site morbidity.

INTRODUCTION

Autogenous bone grafts from the iliac crest have long been the gold standard for repair and reconstruction of bone, satisfying all of the requirements for bone generation (41, 63) and yielding high fusion rates (63). Unfortunately, harvesting of autogenous bone grafts is associated with the risk of iliac crest donor site morbidity (3, 4, 17, 20, 25, 28, 63, 69, 79). Indeed, the overall morbidity associated with iliac crest bone harvesting in lumbar fusion approaches 30% (49). Complications include vascular and nerve injuries, iliac wing fracture, haematoma, infection, cosmetic disfigurement, and particularly chronic pain.

Donor site pain is usually moderate in intensity, but is described as “significant”, “severe”, or “unacceptable” by some patients (20, 28, 69). In one large study (n = 300), 17% of patients who underwent autogenous bone grafting reported debilitating donor site pain or pain that required narcotic analgesic medication for at least 3 months after surgery (63). Pain usually lasts for more than a year in approximately one-quarter of the affected patients (20, 25, 28); in some individuals, it is severe enough to limit ambulation for at least 2 years after surgery (25).

Over the years, different bone substitutes have been proposed in an attempt to avoid the donor site morbidity associated with autogenous bone grafts, and to provide suitable alternatives when insufficient donor bone is available (table I). A true bone
substitute that is able to induce bone healing and formation requires two components: an osteoconductive scaffold to permit bony apposition, and an osteoinductive signal, which will allow the recruitment and differentiation of bone forming cells from the host’s tissues. Allografts are a popular alternative to autogenous bone grafts. However, it appears that only osteoconductive capacity is retained, with osteoinductive properties being lost. Furthermore, the quality of allografts is often inconsistent and there is a limited, but existing, potential for transmission of infectious disease. In the 1960s, Urist et al (7) discovered the bone morphogenetic proteins (BMPs): soluble bone matrix glycoproteins that induce the differentiation of osteoprogenitor cells into osteogenic cells. Their potential to act as bone inductive agents, which could be used in several applications where bone generation was needed, was soon recognised. Following the isolation and expression of BMP complementary DNA, two recombinant human proteins – rhBMP-2 and rhBMP-7 (OP-1) – are now commercially available for acute and revision orthopaedic surgery.

Demineralised bone matrix (DBM), which is made by decalcifying allogeneic bone while maintaining the extracellular matrix appears to maintain a certain osteogenic potential owing to its content of expressed BMPs. However, variability in BMP content (particularly BMP-2, BMP-4, and BMP-7) within different lots of the same DBM product can be as much as four-fold. In addition, the BMP content of DBM is low; it has been estimated that it would take 100 kg of Grafton® DBM to achieve a 6 mg dose of rhBMP-2. Despite manufacturing processing, the potential for transmission of diseases due to the human origin of DBM also cannot be ruled out. Numerous other bone substitutes have been developed based on calcium ceramics (e.g. hydroxyapatite, beta-, bi-, or tri-calcium phosphates). These offer purely osteoconductive properties; however, it seems that those with a higher microporosity and high interconnection structure offer optimal capillarity and wicking, allowing migration of osteogenic cells and growth factors. Some also provide structural strength.

This article will review the role of BMPs in bone morphogenesis and the subsequent investigation of rhBMP-2 for orthopaedic application.

**BONE MORPHOGENESIS**

Bone is a rigid form of specialised connective tissue consisting largely of Type I collagen fibres. Mineralisation of the collagen bone matrix with solid particles of calcium phosphate in the form of hydroxyapatite crystals accounts for the rigidity of bone structure. Despite this rigidity, bone is a dynamic tissue that is continually being remodelled by the cells within it. This process enables the turnover and replacement of the matrix in the interior of the bone throughout an individual’s life.

Three major cell types are found throughout the extracellular bone matrix: osteoblasts, osteocytes and osteoclasts. Osteoblasts, which develop from
mesenchymal stem cells, are responsible for bone formation, producing and secreting components of bone matrix, including Type I collagen, osteocalcin, osteonectin and alkaline phosphatase. They undergo several fates in humans. Some osteoblasts remain active, synthesising and regulating the deposition and mineralisation of bone, while others become embedded in their own secretions and are trapped within the hard mineralised bone matrix. These cells form resting osteocytes, which are incapable of cell division and are chiefly responsible for bone maintenance. Osteoclasts, which are also present in the bone matrix, are giant multinucleated cells that derive from haemopoietic stem cells in the bone marrow. These cells are involved in bone resorption and remodelling (fig 1).

Ossification of bone is a multifaceted process. Mesenchymal stem cells are attracted to and attach to the bone matrix, where they proliferate and differentiate into chondrocytes and osteoblasts. At the same time, proliferation and differentiation of haematopoietic stem cells to form osteoclasts enables the destruction of the original matrix to be coupled to the formation of new bone. Neovascularisation and mineralisation are also taking place. The BMPs appear to have roles in both the chemotaxis, mitogenesis and differentiation of mesenchymal stem cells, as well as the promotion of angiogenesis.

**BONE MORPHOGENETIC PROTEINS**

In 1971, Marshall Urist (75) coined the term “bone morphogenetic protein” to describe a protein component of DBM that could induce new bone formation in a manner recapitulating the normal events of endochondral ossification. A Medline search for the term today (March 2005) reveals the subsequent publication of more than 5,500 articles on BMPs, which, in addition to roles in bone and cartilage morphogenesis, are also implicated in prenatal development, postnatal growth of soft tissues, including eye, heart, lung, kidney, and skin, and various pathological processes, such as atherosclerosis, hypertension, and prostate cancer.

The human genome encodes more than 20 BMPs. The proteins have been grouped into subsets based on amino acid sequence homology (table II). With the exception of BMP-1, which was mistakenly classified as a BMP, these low-molecular weight, non-collagenous glycoproteins belong to the transforming growth factor-beta (TGF-β) superfamily. Other members of the TGF-β family are also involved in developmental processes, particularly embryonic development and the regeneration of skeletal tissues in adults. BMP-2, BMP-4 through to BMP-7, and BMP-9 have been shown to induce intramembranous and endochondral bone formation (58). Of these, BMP-2, BMP-6 and BMP-9 appear to have important roles in the induction of mesenchymal cell differentiation into osteoblasts (15).

BMPs are synthesised by osteoblasts as 400–500 amino acid peptides, each consisting of a leader sequence, a propeptide, and a mature osteoinductive domain at the carboxy-terminal (fig 2). The mature domain of each BMP contains a region of seven conserved cysteine amino acids, six of which are involved in forming a characteristic structural motif: a cysteine-knot with two finger-like double-
stranded sheets. The molecules exist mostly as biologically active homodimers linked by a disulphide bond between the seventh conserved cysteine residues, although naturally occurring hetero-

dimers and multimers that retain biological activity also exist. Prior to secretion from the osteoblast, BMP molecules are cleaved between the propeptide and mature regions to release the active BMP dimer.

Pre-clinical evidence suggests that active BMP dimers act as a chemoattractant for undifferentiated mesenchymal stem cells, causing them to move into the area of bone defect or injury (78). BMP then binds to serine/threonine kinase receptors (BMP receptor Type I and II) that are displayed on the stem cells’ surface. Following ligand binding, the Type II receptor homodimer cross-phosphorylates the Type I receptor in the GS region, activating its kinase domain (fig 3) (19). The Type I receptor kinase then initiates downstream signalling by phosphorylating and activating intracellular messenger proteins called Smads. Distinct Type I and Type II receptors have been identified (33). The specific Smad protein to be activated depends on the type of BMP ligand and the Type I receptor it binds to. BMP-2, for example, binds to BMPIa and BMPIb receptors, whereas BMP-7 binds to ALK-2 or BMP-Ib receptors.

Osteoinduction appears to be mediated by R-Smads (Smads 1, 5, and 8). Smads 1 and 5 are

Table II. — Bone morphogenetic proteins: grouped by amino acid sequence homology (59). Adapted with the kind permission of the publishers (Medtronic Sofamor Danek) from Rodriguez WJ, Coakley MB. Basic bone biology. Training and development. Medtronic 2002

<table>
<thead>
<tr>
<th>BMP group members</th>
<th>Alternative nomenclature</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMP-2</td>
<td>BMP-2b</td>
</tr>
<tr>
<td>BMP-4</td>
<td></td>
</tr>
<tr>
<td>BMP-3</td>
<td>Osteogenin</td>
</tr>
<tr>
<td>BMP-3b</td>
<td>GDF-10</td>
</tr>
<tr>
<td>BMP-5</td>
<td></td>
</tr>
<tr>
<td>BMP-6</td>
<td></td>
</tr>
<tr>
<td>BMP-7</td>
<td>OP-1</td>
</tr>
<tr>
<td>BMP-8</td>
<td>OP-2</td>
</tr>
<tr>
<td>BMP-9</td>
<td>OP-3</td>
</tr>
<tr>
<td>BMP-10</td>
<td></td>
</tr>
<tr>
<td>BMP-11</td>
<td></td>
</tr>
<tr>
<td>BMP-12</td>
<td>GDF-7 or CDMP-2</td>
</tr>
<tr>
<td>BMP-13</td>
<td>GDF-6 or CDMP-1</td>
</tr>
<tr>
<td>BMP-14</td>
<td></td>
</tr>
<tr>
<td>BMP-15</td>
<td>GDF-9b</td>
</tr>
</tbody>
</table>

BMP = bone morphogenetic protein; CDMP = cartilage-derived morphogenetic protein; GDF = growth / differentiation factor; OP = osteogenic protein.

Fig. 2. — Activation of BMP (59). Reproduced with the kind permission of the publishers (Medtronic Sofamor Danek) from Rodriguez WJ, Coakley MB. Basic bone biology. Training and development. Medtronic 2002.

activated by BMP-Ia and BMP-Ib receptors, whereas Smads 1, 5, and 8 can be activated by ALK-2 receptors. Once activated, R-Smads combine with Smad 4 to form a nuclear signalling complex that is capable of altering specific patterns of gene expression to promote cell proliferation and stimulate the concentration-dependent transformation of daughter cells into chondroblasts or osteoblasts. Smads 6 and 7 compete for phosphorylation of Smad 4, and appear to be involved in the inhibition of osteoinduction; the mechanism of action is not yet understood, but probably involves negative feedback (46).

BMPs also promote angiogenesis during ossification (18, 47, 48, 50, 72) via a mechanism that involves osteoblast-derived VEGF-A (18). Studies in cell and animal models have shown that BMP-induced neovascularisation is critical for bone induction (47, 48, 50), probably playing an essential role in enabling the recruitment of BMP receptor-positive cells.

RECOMBINANT HUMAN BMP-2 IN ORTHOPAEDIC APPLICATIONS

Endogenous BMPs are typically found in the body at a concentration of less than 2 mg/kg in cortical bone (55) and are difficult to extract in sufficient quantities for clinical use. The isolation and cloning of the human BMP-2 gene and the subsequent production of its recombinant form (rhBMP-2; dibotermin alfa) in large quantities was, therefore, a landmark.

Recombinant human BMP-2 is highly osteoinductive (41). In vitro studies show that mesenchymal stem cells incubated with rhBMP-2 have increased alkaline phosphatase activity and undergo matrix mineralisation (16, 57). When implanted in vivo, rhBMP-2 induces osteoinduction by recruiting mesenchymal stem cells, then inducing the proliferation and differentiation of these cells into an osteoprogenitor lineage. The bone formed has exactly the same composition as bone elsewhere in the body (76).

In the human body, tissue clearance of BMPs is rapid; hence, a carrier is required to retain an effective concentration of rhBMP-2 at the site of implantation. The carrier also provides a scaffold for new bone formation. Early studies in animal segmental defect models explored several materials (23, 36, 44, 53, 65). Type I collagen has proved to be the most bioactive, biocompatible and biodegradable carrier, and all rhBMP products currently on the market incorporate forms of collagen I.

In Europe, rhBMP-2 is commercially available as the active pharmaceutical ingredient of the InductOS™ implant kit (Medtronic Sofamor Danek and Wyeth Pharmaceuticals) for treatment of acute open tibial fracture. The kit contains rhBMP-2 as a lyophilised powder, which is dissolved in sterile water and applied to an absorbable collagen sponge (ACS) made of Type I bovine collagen. In Europe and the USA, rhBMP-2 is available with ACS as the InFUSE™ bone graft (Medtronic Sofamor Danek), which includes a perforated, threaded, cylindrical, tapered, titanium interbody fusion cage, and is available for the clinical treatment of degenerative lumbar disc disease.

Few complications have been observed during clinical trials with rhBMP-2 at therapeutic dosages, despite the fact that BMPs – by virtue of their nature – have the potential to induce heterotopic bone formation. As with all exogenous protein molecules, antibody formation is a concern. Antibodies to rhBMP-2 and the bovine collagen carrier have been reported to occur in approximately 6% and 5-20% of patients, respectively, but titres have been low and transient and no clinical sequelae have been observed (73).

SPINAL FUSION

Fusion for chronic low back pain due to degenerative disc disease seems to alleviate pain in selected groups of patients (21). The oldest surgical technique is that of non-instrumented fusion (posterolateral or interbody). Different surgical options, combined with different types of fixation instrumentation have more recently become popular, including anterior lumbar interbody fusion (ALIF) with supplemental posterior instrumentation, posterior lumbar interbody fusion (PLIF) with posterolateral instrumentation, and transforaminal lumbar interbody fusion (TLIF) with posterolateral...
instrumentation (51). However, the optimal technique for performing lumbar spinal fusion remains a subject of controversy. Proponents of the newer techniques claim that they permit better rates of solid arthrodesis and improved clinical results. For instance, proponents of so-called “360° fusion”, which combines interbody with posterior fixation, argue that the technique gives increased stability. Nevertheless, to date there is only a limited number of well-conducted studies that have compared instrumented with non-instrumented fusion. Rates of solid fusion have been inconsistent. Even with autogenous bone grafts, pseudarthrosis rates of up to 35% have been reported (49). It is difficult to predict which patients will develop a pseudarthrosis (9). Although it appears that the fusion rate is indeed better with instrumented procedures, clinical results do not differ. Fritzell et al did not find any differences in clinical outcome between non-instrumented, posterolateral and 360° fusion during a high quality, randomised study (22).

The clinical use of rhBMP-2 as an osteoinductive alternative to autogenous bone graft has been investigated at posterolateral, anterior, posterior and transforaminal lumbar sites. Both instrumented and non-instrumented fusion have been studied. The results of these studies are summarised in table III and reviewed in detail in the sections below. Two in-depth reviews of rhBMP-2 have also been published recently, which provide deeper insight into the pre-clinical development of the agent than provided here (34, 46).

Posterolateral fusion

Early pre-clinical studies of posterolateral fusion showed that while rhBMP-2 plus ACS achieved fusion rates of 100% in lower animal models (rabbit and dog) (60, 64), in higher animal models the ACS appeared to be compressed by muscle fibres, hampering bone formation (43). Different carriers for rhBMP-2 have been investigated in an attempt to avoid this problem.

A biphasic calcium phosphate (BCP) ceramic carrier (60% hydroxyapatite; 40% tricalcium phosphate) has been developed (65). When used in conjunction with the BCP carrier in a non-human primate model, rhBMP-2 dose-dependent fusion was observed. During the same investigation, no fusion was observed in animals receiving autogenous bone graft. Two pilot studies (table III) suggest that these findings are also applicable to humans (6, 42). In the first study, eight patients were treated bilaterally with rhBMP-2 (20 mg) plus BCP (10 cm³); a second group of seven patients was treated unilaterally with rhBMP-2 (15 mg) plus BCP (7 cm³), and contralaterally with autogenous bone graft (6). After 12 months, solid posterolateral fusion had occurred in all patients receiving rhBMP-2 bilaterally. Incomplete fusion was observed in the second group, although fusion was more likely on the side receiving rhBMP-2 than on the side receiving autogenous bone graft (86% vs 57%). Clinical success was achieved in 100% of patients receiving bilateral rhBMP-2, compared with 87% of patients receiving rhBMP-2 and autogenous bone graft. In the second study (42), patients received either rhBMP-2 (2.0 mg/ml) plus BCP with instrumentation (n = 11), rhBMP-2 (2.0 mg/ml) plus BCP without instrumentation (n = 9) or autogenous bone graft with posterior instrumentation (n = 5) (6). After 17 months, successful fusion was observed in all patients receiving rhBMP-2, compared with only 2/5 patients receiving the autogenous bone graft. Further studies are ongoing.

The pre-clinical development of other carriers is continuing. Recently, improved fusion rates have been reported with rhBMP-2 applied to carriers containing lower concentrations of hydroxyapatite (63, 67). Nano-hydroxyapatite/collagen composites have also shown promising results (39, 70). Other approaches include adding allograft chips or resorbable ceramic granules to ACS to prevent it from being compressed. Results from animal models demonstrate 100% fusion rates when rhBMP-2 is applied to these carriers (2, 45, 68).

Anterior lumbar interbody fusion

The anterior lumbar site is less challenging than the posterolateral environment and has become a popular alternative in spinal arthrodesis, enabling direct access to the anterior spinal column, indirect
Table III. — Clinical studies with rhBMP-2 in spinal interbody fusion (34). Reproduced (and updated) with the kind permission of the publishers (Ashley Publications) from Khan SN, Lane JM. The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in orthopaedic applications. Expert Opin Biol Ther 2004 ; 4 : 741-748

<table>
<thead>
<tr>
<th>Trial (approach)</th>
<th>Comparators</th>
<th>Patients (n)</th>
<th>Carrier / cage or dowel</th>
<th>Follow-up (months)</th>
<th>Fusion rate (%)</th>
<th>Clinical outcomes</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posterolateral fusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P, NB, R, C</td>
<td>Bilateral rhBMP-2 (20 mg/10 cm³)</td>
<td>8</td>
<td>BCP / -</td>
<td>12</td>
<td>100%</td>
<td>Clinical success in 100% in the bilateral rhBMP-2 group vs 87% in group also receiving autogenous bone graft</td>
<td>Boden et al 2002 (6)</td>
</tr>
<tr>
<td></td>
<td>Unilateral rhBMP-2 (15 mg/7 cm³) plus contralateral autogenous bone graft</td>
<td>7</td>
<td>BCP / -</td>
<td></td>
<td>87%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>rhBMP-2 (2.0 mg/ml)+BCP+ instrumentation</td>
<td>11</td>
<td>BCP / -</td>
<td>17</td>
<td>100%</td>
<td>Clinical success equivalent between groups</td>
<td>Luque 2002 (42)</td>
</tr>
<tr>
<td></td>
<td>rhBMP-2 (2.0 mg/ml) no instrumentation</td>
<td>9</td>
<td>BCP / -</td>
<td></td>
<td>100%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Autogenous bone graft + instrumentation</td>
<td>5</td>
<td>/ -</td>
<td></td>
<td>40%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anterior lumbar interbody fusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P, NB, R, C (open or laparoscopic)</td>
<td>rhBMP-2 (1.5 mg/ml)</td>
<td>11</td>
<td>ACS / titanium cage</td>
<td>6</td>
<td>100%</td>
<td>Pain improved earlier in the rhBMP-2 group</td>
<td>Boden et al 2000 (8)</td>
</tr>
<tr>
<td></td>
<td>Autogenous bone graft</td>
<td>3</td>
<td>- / titanium cage</td>
<td></td>
<td>66%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P, NB, R, C (open)</td>
<td>rhBMP-2 (1.5 mg/ml)</td>
<td>143</td>
<td>ACS / titanium cage</td>
<td>24</td>
<td>95%</td>
<td>Reduced operative times, blood loss, and hospital duration in the rhBMP-2 group</td>
<td>Burkus et al 2002 (11)</td>
</tr>
<tr>
<td></td>
<td>Autogenous bone graft</td>
<td>136</td>
<td>- / titanium cage</td>
<td></td>
<td>89%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P, NB, R, C (open)</td>
<td>rhBMP-2 (1.5 mg/ml)</td>
<td>22</td>
<td>ACS / titanium cage</td>
<td>12</td>
<td>100%</td>
<td>Rate of bone formation greater in the rhBMP-2 group</td>
<td>Burkus et al 2003 (10)</td>
</tr>
<tr>
<td></td>
<td>Autogenous bone graft</td>
<td>20</td>
<td>- / titanium cage</td>
<td></td>
<td>95%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P, NB, R, C (open)</td>
<td>rhBMP-2 (1.5 mg/ml)</td>
<td>24</td>
<td>ACS / allograft bone dowels</td>
<td>24</td>
<td>100%</td>
<td>Blood loss reduced and Oswestry Disability Index improved to greater extent in the rhBMP-2 group</td>
<td>Burkus et al 2002 (13)</td>
</tr>
<tr>
<td></td>
<td>Autogenous bone graft</td>
<td>22</td>
<td>- / allograft bone dowels</td>
<td></td>
<td>68.4%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P, NB (laparoscopic)</td>
<td>rhBMP-2 (1.5 mg/ml)</td>
<td>136</td>
<td>ACS / titanium cage</td>
<td>12</td>
<td>&gt; 90%</td>
<td>Hospital duration reduced in the rhBMP-2 group</td>
<td>Zdeblick et al 2001 (80)</td>
</tr>
<tr>
<td></td>
<td>Autogenous bone graft (historical control)</td>
<td>266</td>
<td>- / titanium cage</td>
<td></td>
<td>&gt; 90%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trial (approach)</td>
<td>Comparators</td>
<td>Patients (n)</td>
<td>Carrier / cage or dowel</td>
<td>Follow-up (months)</td>
<td>Fusion rate (%)</td>
<td>Clinical outcomes</td>
<td>Reference</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------------</td>
<td>--------------</td>
<td>------------------------</td>
<td>------------------</td>
<td>----------------</td>
<td>------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>P, NR, NB (laparoscopic)</td>
<td>rhBMP-2 (1.5 mg/ml)</td>
<td>22</td>
<td>ACS / titanium cage</td>
<td>6</td>
<td>100%</td>
<td>Improvements vs baseline in Oswestry Disability Index, pain and functional capacity</td>
<td>Kleeman et al 2001 (35)</td>
</tr>
<tr>
<td>Integrated analysis (open or laparoscopic)</td>
<td>rhBMP-2 (1.5 mg/ml)</td>
<td>277</td>
<td>ACS / titanium cage</td>
<td>24</td>
<td>94.4%*</td>
<td>Improved low back pain* and reduced operative times*, blood loss*, hospital duration*, re-operation rate*, and time before returning to work* in the rhBMP-2 group</td>
<td>Burkus et al 2003 (12)</td>
</tr>
<tr>
<td></td>
<td>Autogenous bone graft</td>
<td>402</td>
<td>- / titanium cage</td>
<td></td>
<td>89.4%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Posterior lumbar interbody fusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P, NB, R, C (Study halted)</td>
<td>rhBMP-2 (1.5 mg/ml)</td>
<td>34</td>
<td>ACS / titanium cage</td>
<td>24</td>
<td>92.3%</td>
<td>Improved back and leg pain and Oswestry Disability Index in rhBMP-2 group, but heterotopic bone formation seen in spinal canal</td>
<td>Haid et al 2004 (27)</td>
</tr>
<tr>
<td></td>
<td>Autogenous bone graft</td>
<td>33</td>
<td>- / titanium cage</td>
<td></td>
<td>77.8%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transforaminal lumbar interbody fusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P, NB, NR</td>
<td>rhBMP-2 (1.5 mg/ml)</td>
<td>21</td>
<td>ACS / titanium cage</td>
<td>3-18</td>
<td>95.2%</td>
<td>58% of patients receiving iliac crest autograft complained of pain 6 months post-surgery</td>
<td>Mummaneni et al 2004 (52)</td>
</tr>
<tr>
<td></td>
<td>Autogenous bone graft</td>
<td>19</td>
<td>- / titanium cage</td>
<td></td>
<td>94.7%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P, NB, NR</td>
<td>rhBMP-2 (1.5 mg/ml)</td>
<td>43</td>
<td>ACS / biodegradable implant</td>
<td>6</td>
<td>98%</td>
<td>Improvements vs baseline in Oswestry Disability Index in 68% of patients at 6 months</td>
<td>Lanman &amp; Hopkins 2004 (38)</td>
</tr>
<tr>
<td>NB, NR</td>
<td>rhBMP-2 (1.5 mg/ml)</td>
<td>22</td>
<td>ACS / biodegradable implant</td>
<td>6-18</td>
<td>97.4%</td>
<td>Operating time, blood loss and hospital stay consistent with previous reports. No infections, deep vein thromboses or implant complications</td>
<td>Kuklo et al 2004 (37)</td>
</tr>
</tbody>
</table>

C = controlled ; NB = non-blinded ; NR = non-randomised ; P = prospective ; R = randomised

*p < 0.05 vs autogenous bone graft

*Integrated analysis of four studies, including Burkus et al 2002 (11) and Kleeman et al 2001 (35) ; other studies unspecified.
decompression of the intervertebral foramen, and improvement of sagittal balance, while avoiding paraspinal muscle trauma and denervation (51). Early pre-clinical studies found that rhBMP-2 offered a safe and effective alternative to autogenous bone grafts for ALIF (7, 62, 80). In a sheep model of ALIF, radiological fusion occurred earlier and stiffness was consistently increased following insertion of a titanium interbody fusion cage filled with rhBMP-2 plus ACS compared with a similar cage filled with autogenous bone graft (62). Indeed, fusion rates were three times higher with rhBMP-2 than with autogenous bone graft. Similar results were seen in goats undergoing laparoscopic ALIF: fusion occurred in 95% of cages filled with rhBMP-2 plus ACS, compared with 48% of cages filled with autogenous bone graft (80).

Subsequently, two doses of rhBMP-2 were compared in primates (7). Titanium interbody fusion cages filled with rhBMP-2 plus ACS (0.75 or 1.5 mg/ml) or rhBMP diluent (control) were randomly inserted into eight rhesus monkeys undergoing laparoscopic ALIF. After 24 weeks, all animals that received rhBMP-2 had complete and solid bone bridging, whereas fusion had not occurred in the control animals. Computer tomography (CT) scans showed that fusion occurred earlier in animals that received the higher dose (1.5 mg/ml) of rhBMP-2. Hecht et al (29) reported similar findings when they compared the effects of a smooth cortical allograft dowel packed with either rhBMP-2 (1.5 mg/ml) plus ACS or autogenous bone graft in six rhesus monkeys undergoing ALIF. Extensive fusion occurred in all animals that received rhBMP-2, with radiographical evidence of fusion apparent as early as 8 weeks. In contrast, partial fusion occurred in only one of the animals that received autogenous bone graft, after 6 months.

A pilot study was conducted to investigate the effect of rhBMP-2 as a substitute for autogenous iliac crest bone graft for ALIF in humans (Table III) (8). The study involved patients with single-level symptomatic lumbar degenerative disc disease undergoing ALIF by an open or laparoscopic approach. Patients received two titanium interbody fusion cages filled with rhBMP-2 (1.5 mg/ml) plus ACS or autogenous bone graft from the anterior iliac crest. After 3 months, 10/11 patients who received rhBMP-2 versus 2/3 patients receiving autogenous bone graft had solid interbody fusions. By 6 months, all patients in the rhBMP-2 group had solid interbody fusions, versus 66% in the control group. Pain (rated on the Oswestry Low Back Pain Disability Questionnaire) improved sooner (after 3 months) in the investigational than in the control group, while both groups showed similar improvement after 6 months.

The pilot study was expanded to include a total of 279 patients undergoing single-level ALIF via an open approach (Table III) (11). Patients were randomised to implantation of titanium interbody fusion cages filled with either rhBMP-2 plus ACS (1.5 mg/ml) (n = 143) or autogenous bone graft (n = 136). Eight patients (5.9%) who received the autogenous bone graft experienced adverse events relating to harvesting of bone at the iliac crest, including nerve injury, fracture, infection and haematoma. All patients in the group reported donor site pain. The incidence of pain was highest immediately following the operation (mean pain score: 12.7 on scale of 0-20) and decreased with time; however 32% of patients were still experiencing pain 24 months later (mean pain score: 1.8). Patients treated with rhBMP-2 did not undergo a bone harvesting procedure and consequently, compared with patients receiving the autogenous bone graft, operative times were shorter (1.7 vs 2.0 hours), operative blood loss was less (109 vs 154 ml), and time spent in hospital was reduced (3.1 vs 3.3 days). After 24 months, 95% of patients who received rhBMP-2 and 89% of patients who received autogenous bone graft had radiographic and CT evidence of interbody fusion. In no case in either treatment group did ossification extend outside of the vertebral column. Back pain, leg pain and neurologic status improved in both treatment groups to a similar extent. Patients who were working before surgery were able to return to work within a similar time frame in both groups (median: 63.5 (rhBMP-2) vs 64.5 days (autogenous bone grafts), respectively) (fig 4).

A smaller study by the same group recorded similar effects (Table III) (10). Radiographic evidence of osteoinduction was apparent within
6 months of implanting titanium interbody fusion cages filled with either rhBMP-2 (1.5 mg/ml) plus ACS (22/22 patients) or autogenous bone graft (19/20 patients). CT scans showed that the rate of bone formation in the rhBMP-2 group exceeded that seen in the autogenous bone graft group, almost doubling in the first 6 months, and increasing by a factor of almost 2.5 by 24 months. All new bone formation outside the cages occurred within the disc space with no evidence of ectopic bone formation.

The comparative effects of using rhBMP-2 (1.5 mg/ml) plus ACS or autogenous bone graft implanted within a cortical threaded allograft bone dowel, rather than a titanium fusion cage, were investigated in 46 patients undergoing single-level ALIF for degenerative disc disease (Table III) (13). Operative times and time spent in hospital were similar in patients randomised to receive rhBMP-2 (n = 24) or autogenous bone graft (n = 22); however, operative blood loss was reduced in the rhBMP-2 group. A statistically significantly greater improvement in Oswestry Disability Index was also seen in the rhBMP-2 group at 3 and 6 months post-surgery. After 12 months, all patients in the rhBMP-2 group had solid interbody fusions that remained fused at 24 months. In contrast, fusion rates in the autogenous bone graft group were lower (89.5% at 12 months and 68.4% at 24 months). Neurologic status, back and leg pain also improved to a greater extent in the rhBMP-2 group, and 24 months post-surgery more patients in this group were employed than had been before the operation (rhBMP-2: 66.7% vs 45.8%; autogenous bone graft: 35.0% vs 40.9%).

In recent years, surgeons have combined modern laparoscopic techniques with ALIF, to achieve what many believe to be a less invasive approach. Zdeblick et al (80) examined the effect of implanting titanium interbody fusion cages filled with rhBMP-2 (1.5 mg/ml) plus ACS via a laparoscopic approach in 136 patients undergoing ALIF for treatment of single-level degenerative disc disease. Operative times and blood loss were similar to historical control values taken from a study on 266 patients in whom laparoscopic insertion of titanium interbody fusion cages filled with autogenous bone graft had been performed; however, time spent in hospital was markedly reduced. After 12 months, fusion rates were similar to historical control values for laparoscopic implantation of rhBMP-2 and laparoscopic implantation of autogenous bone graft. Similar results were reported from a case series in which titanium interbody fusion cages filled with rhBMP-2 plus ACS were inserted laparoscopically in 22 patients with degenerative disc disease (35). Significant improvement in Oswestry Disability Index, pain and functional capacity was observed after 6 and 12 months (p < 0.001) and all employable patients had returned to work within 12 months. Investigators observed contiguous ossification in 21 evaluable patients 6 months post-surgery. While two complications occurred as a result of the laparoscopic approach, no complications were attributed to use of rhBMP-2.

To confirm the statistical significance of the observed effects of rhBMP-2 during ALIF, Burkus et al (12) performed an integrated analysis of data from four multicentre trials. In total, 277 patients
who had received rhBMP-2 and 402 who had received autogenous bone graft were included in the analysis. All patients had undergone a single ALIF procedure—either by open (n = 279) or laparoscopic (n = 400) approach. Compared with patients receiving autogenous bone graft, those in the rhBMP-2 group had significantly shorter operative times (2.7 vs 1.8 hours; p < 0.001), reduced operative blood loss (193 vs 127 ml; p = 0.024), fewer days in hospital (3.1 vs 2.2 days; p < 0.001), and demonstrated higher fusion rates after 24 months (89.4% vs 94.4%; p = 0.022). In addition, low back pain improved at all time points (p < 0.01), patients underwent fewer re-operations (7.96% vs 2.89%; p = 0.0036), and the median time that elapsed before patients returned to work was less (170.5 vs 116.0 days; p = 0.0156).

POSTERIOR LUMBAR INTERBODY FUSION

During PLIF, lateral dissection is limited to the facet joints, eliminating the exposure of the transverse process. The technique enables direct neural decompression, combined with restoration of disc space height and sagittal balance. Preliminary data on the use of rhBMP-2 in PLIF have been reported from a single pilot study in 67 patients undergoing lumbar decompression for single-level degenerative disc disease (table III) (27). Patients had been randomised to receive stand-alone titanium interbody fusion cages packed with either rhBMP-2 plus ACS (n = 34) or autogenous bone graft (n = 33). Mean operative time was 2.6 vs 3.0 hours, and mean blood loss was 322.8 vs 372.7 ml, respectively. Back and leg pain and Oswestry Disability Index scores improved in both the rhBMP-2 and autogenous bone graft groups. Fusion rates were 92.3% for rhBMP-2 and 77.8% for autogenous bone graft after 24 months. There were no statistically significant differences between the groups for any of these parameters. Despite these beneficial outcomes, the trial was stopped following the detection of heterotopic bone formation in the spinal canal adjacent to the fusion cages in 24 patients receiving rhBMP-2 and 4 patients receiving autogenous bone graft. It was thought this effect might have resulted from cages that were not correctly recessed within the confines of the disc space. Sagittal balance of the instrumented vertebral motion segment was also thought to have played a role. Concerns were also expressed about the long-term mechanical stability of stand-alone cylindrical cages, which are no longer widely used for spinal surgery. Modified surgical techniques and selection of patients with less vertebral slip may improve outcomes. Further studies with rhBMP-2 in posterior lumbar interbody fusion are currently ongoing.

TRANSFORAMINAL LUMBAR INTERBODY FUSION

TLIF involves placing bone grafts and titanium cages into a distracted disc space via the posterolateral transforaminal route, with a pedicle screw construct. As the technique does not require anterior or abdominal exposure, it should avoid vascular, abdominal wall and autonomic complications (51). Data have been reported on the use of rhBMP-2 plus ACS compared with autograft in TLIF (table III) (52). Forty patients received titanium interbody fusion cages packed with either rhBMP-2 plus ACS (n = 21) or autogenous bone graft (n = 19) in a non-randomised fashion. During a mean follow-up of 9 months, solid fusion was observed in all but one of the patients who received rhBMP-2 plus ACS. Similarly, one pseudoarthrosis was detected in patients who received autogenous bone graft. Notably, 58% of patients in whom an iliac crest autograft had been used complained of donor site pain 6 months post-surgery.

More recently, several studies have explored the use of synthetic poly (L-lactide-co-D, L-lactide) bioresorbable implants packed with rhBMP-2 as an alternative to titanium cages during TLIF (table III) (37, 38). These bioresorbable implants provide immediate stability whilst allowing gradual transfer of load to the developing fusion mass. A prospective study was conducted in 43 patients with degenerative disc disease; nearly one-third of participants underwent multi-level fusions with bioresorbable implants packed with rhBMP-2 plus ACS (38). Improvements were seen in Oswestry Disability Index in 68% of patients after 6 months.
Solid interbody fusions were observed in 98% of patients. After 12 months, complete bridging of bone was seen in all patients for whom CT scans were available (n = 11). In another study (a consecutive case series of 22 patients undergoing single or multiple-level TLIF with bioresorbable implants packed with rhBMP-2 plus ACS) bridging bone was observed within 3 months (37). Solid fusion was observed in 97.4% (38/39) of fusion levels between 6 and 12 months post-surgery. The fusion mass appeared to increase with time. Notably, there were no reports of infections or implant complications.

**TIBIAL TRAUMA AND NON-UNION**

Standard care for acute open tibial fractures usually includes external fixation or intramedullary nail fixation and routine soft tissue management. Limited vascular supply, sparse tissue coverage, and a high risk of infection at the fracture site can hamper successful healing in spite of adequate and early management. Indeed, healing times for tibial fractures are frequently longer than for other fractures.

Based on the observed effects of rhBMP-2 plus ACS on healing in segmental defect models, its application to long bone fractures was investigated in goats (77). Bilateral closed tibial fractures were created, then stabilised using external fixation in 16 animals. The goats were randomised to receive rhBMP-2 (0.86 mg) plus ACS or buffer plus ACS applied to one tibial fracture; the contralateral fracture served as control. After 3 weeks, increased callus was observed in tibiae treated with rhBMP-2 plus ACS, and after 6 weeks radiographic healing scores were superior in this group compared with both controls.

A pilot study went on to investigate the effect of rhBMP-2 (0.43 mg/ml) plus ACS on fracture healing in 12 patients with open tibial fractures (Gustilo-Anderson classification II or higher) (56). Recombinant human BMP-2 plus ACS was associated with fracture healing (without secondary intervention) in 9/12 treated patients within 6 months.

More recently, a prospective, randomised, single-blind, multicentre study was conducted in 450 patients with open tibial fracture to investigate the effect of rhBMP-2 plus ACS (0.75 or 1.5 mg/ml), compared with standard care alone (26). The investigators found a significant, dose-dependent decrease in the proportion of patients who required secondary intervention to promote healing in the groups receiving rhBMP-2 (0.75 or 1.5 mg/ml), compared with the standard care group (37% and 26% vs 46%; p = 0.0004). The risk of secondary intervention was reduced by 44% in patients receiving rhBMP-2 (1.5 mg/ml) compared with standard care alone (p = 0.0005). Similarly, fewer invasive secondary interventions were required in this group: a relative risk reduction of 52% in the invasive intervention rate (p = 0.0264).

Fracture healing (based on both clinical and radiological assessment) was significantly accelerated in the rhBMP-2 (1.5 mg/ml) group, compared with standard care – an effect that was seen from 10 weeks to 12 months after definitive wound closure (p = 0.0008) (fig 5). Indeed, there was a 39-day difference between the time at which fracture healing
occurred in 50% of patients within these groups (145 vs 184 days, respectively). The infection rate at the fracture site was similar overall between the treatment groups. However, it was significantly lower in patients with the most severe injuries (Gustilo-Anderson type-IIIA and IIIB) treated with rhBMP-2 (1.5 mg/ml) than those treated with standard care (24% vs 44%; p = 0.0219). Healing of tibial fractures is classically prolonged in the presence of infection (24, 30). It might be hypothesised, therefore, that in addition to its direct effects on bone morphogenesis, the angiogenic effect of rhBMP-2 may increase protection against infection and thus play an indirect role in acceleration of the healing process. Observed statistically significant differences in terms of wound healing rate and pain that favoured rhBMP-2 (1.5 mg/ml) also suggest evidence of increased vascular supply. More rapid wound healing will also help to protect against infection.

A clinical study programme is underway to evaluate the use of injectable carriers for rhBMP-2, which could extend their use to treatment of patients with closed fractures (reviewed in 66).

CONCLUSIONS

Recombinant human BMP-2 plus ACS appears to offer an effective alternative to autogenous bone graft for spinal interbody fusion procedures, and is capable of producing rates of fusion that equal or exceed those seen with autogenous bone graft, whilst obviating the need for iliac crest bone grafts and associated donor site morbidity. Additional advantages associated with a single surgical site are apparent to both the patient and surgeon, and are reflected by shorter operative times, reduced operative blood loss, and less prolonged periods of time spent in hospital. In addition, rhBMP-2 plus ACS has a positive effect on the healing of fresh tibia fractures, thereby avoiding potential future requirements for bone grafts. The effect of rhBMP-2 plus ACS on nonunions in long bones remains to be determined.

Given the results of the clinical trial programme, hospital and payer models need to be developed to assess the economic impact of using rhBMP-2 plus ACS therapy instead of autogenous iliac crest bone graft. In the USA, economic models for a single level ALIF have been published (1, 54). The findings suggest that a substantial portion of the additional cost of rhBMP-2 plus ACS therapy may be offset by the elimination of complications associated with iliac crest bone graft harvesting, and by reduced surgery, anaesthesia, recovery times, decreased blood loss, shorter in-patient stays, and decreased use of autogenous graft extenders / harvesters and medical / surgical supplies. These models must now be extended to evaluate the comparative effects of rhBMP-2 plus ACS and autogenous bone graft on health-related quality of life and lost productivity in order to estimate the true cost-benefit of rhBMP-2 plus ACS therapy.

REFERENCES


73. Termaat MF, Blokhuis TJ, Den Boer FC et al. The role of bone morphogenetic proteins in bone healing. *Osteo Trauma Care* 2003; 11: 122-125.


